Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - axitinib, quantity: 7 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; triacetin; iron oxide red - for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - axitinib, quantity: 7 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - axitinib, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - axitinib, quantity: 3 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; triacetin; iron oxide red - for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - axitinib, quantity: 5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; triacetin; iron oxide red - for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - axitinib, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy

Ізраїль - англійська - Ministry of Health

teva israel ltd - axitinib - film coated tablets - axitinib 1 mg - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.

Ізраїль - англійська - Ministry of Health

teva israel ltd - axitinib - film coated tablets - axitinib 3 mg - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.

Ізраїль - англійська - Ministry of Health

teva israel ltd - axitinib - film coated tablets - axitinib 5 mg - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy

Європейський Союз - англійська - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - carcinoma, renal cell - protein kinase inhibitors - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.